HUIZ stock recently regained compliance with Nasdaq's minimum bid price requirement, trading at $3.38 as of December 31, 2024, reflecting a 7.12% increase. The launch of its innovative "PrimeMed" insurance product and improved investor confidence are driving positive sentiment. However, the stock remains speculative, with limited upside unless further operational improvements materialize.